Zacks Investment Research upgraded shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) from a hold rating to a strong-buy rating in a research report released on Tuesday morning. The brokerage currently has $26.00 target price on the medical equipment provider’s stock.

According to Zacks, “Lantheus Holdings, Inc. is involved in developing, manufacturing, selling and distributing diagnostic medical imaging agents and products for diagnosis of cardiovascular and other diseases. It serves to hospitals, clinics, group practices, integrated delivery networks, group purchasing organizations, radiopharmacies and wholesalers. Lantheus Holdings, Inc. is based in NORTH BILLERICA, United States. “

A number of other brokerages also recently weighed in on LNTH. BidaskClub downgraded Lantheus Holdings from a strong-buy rating to a buy rating in a research note on Thursday, August 17th. Credit Suisse Group raised their target price on Lantheus Holdings from $14.00 to $19.00 and gave the company a neutral rating in a report on Wednesday, August 2nd. Wells Fargo & Company raised Lantheus Holdings from a market perform rating to an outperform rating in a report on Thursday, November 2nd. Cantor Fitzgerald started coverage on Lantheus Holdings in a report on Monday, July 17th. They set an overweight rating and a $22.00 price objective on the stock. Finally, Jefferies Group LLC lifted their price objective on Lantheus Holdings from $22.00 to $27.00 and gave the stock a buy rating in a report on Friday, November 3rd. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The stock currently has a consensus rating of Buy and a consensus target price of $24.50.

Shares of Lantheus Holdings (LNTH) traded down $0.70 during trading on Tuesday, reaching $22.25. The company had a trading volume of 385,100 shares, compared to its average volume of 564,828. The stock has a market cap of $860.76, a P/E ratio of 20.49, a P/E/G ratio of 1.88 and a beta of 0.92. The company has a debt-to-equity ratio of -3.41, a quick ratio of 2.46 and a current ratio of 2.96. Lantheus Holdings has a 1 year low of $7.95 and a 1 year high of $24.10.

Lantheus Holdings (NASDAQ:LNTH) last posted its quarterly earnings results on Thursday, November 2nd. The medical equipment provider reported $0.24 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.20 by $0.04. Lantheus Holdings had a negative return on equity of 46.45% and a net margin of 9.59%. The company had revenue of $79.94 million during the quarter, compared to the consensus estimate of $77.18 million. During the same period last year, the business earned $0.15 EPS. The business’s quarterly revenue was up 9.4% on a year-over-year basis. research analysts forecast that Lantheus Holdings will post 1.02 earnings per share for the current year.

WARNING: “Lantheus Holdings, Inc. (LNTH) Upgraded to Strong-Buy by Zacks Investment Research” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another domain, it was stolen and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.thecerbatgem.com/2017/11/11/lantheus-holdings-inc-lnth-upgraded-to-strong-buy-by-zacks-investment-research.html.

In related news, insider Michael P. Duffy sold 20,000 shares of the business’s stock in a transaction on Monday, September 11th. The stock was sold at an average price of $16.45, for a total value of $329,000.00. Following the sale, the insider now owns 184,218 shares of the company’s stock, valued at approximately $3,030,386.10. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder Avista Capital Partners Gp, Ll sold 87,939 shares of Lantheus Holdings stock in a transaction on Monday, August 14th. The shares were sold at an average price of $17.40, for a total value of $1,530,138.60. The disclosure for this sale can be found here. In the last ninety days, insiders sold 903,099 shares of company stock worth $15,443,485. 2.30% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently modified their holdings of LNTH. State of Alaska Department of Revenue bought a new position in Lantheus Holdings in the 2nd quarter valued at $102,000. Municipal Employees Retirement System of Michigan bought a new position in Lantheus Holdings in the 2nd quarter valued at $107,000. LS Investment Advisors LLC bought a new position in Lantheus Holdings in the 2nd quarter valued at $112,000. Quantbot Technologies LP bought a new position in Lantheus Holdings in the 2nd quarter valued at $117,000. Finally, Sei Investments Co. raised its position in shares of Lantheus Holdings by 189.6% during the third quarter. Sei Investments Co. now owns 7,829 shares of the medical equipment provider’s stock worth $139,000 after acquiring an additional 5,126 shares during the last quarter. Hedge funds and other institutional investors own 86.60% of the company’s stock.

Lantheus Holdings Company Profile

Lantheus Holdings, Inc is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging.

Get a free copy of the Zacks research report on Lantheus Holdings (LNTH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Lantheus Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus Holdings Inc. and related stocks with our FREE daily email newsletter.